Overall Survival With Enzalutamide in Biochemically Recurrent Prostate Cancer

This presentation, delivered by Dr Stephen J. Freedland, reviews final overall survival results and long-term outcomes from the phase 3 EMBARK trial evaluating enzalutamide-based treatment strategies in patients with high-risk biochemically recurrent prostate cancer without radiographic evidence of metastases. The session contextualizes EMBARK within the evolving management of biochemically recurrent disease and summarizes the trial design, patient population, and treatment arms, including enzalutamide plus androgen deprivation therapy, enzalutamide monotherapy, and androgen deprivation therapy alone. Updated efficacy findings are discussed with a focus on overall survival, as well as key secondary endpoints such as time to first use of new antineoplastic therapy, time to symptomatic skeletal events, and progression-free survival on first subsequent therapy. Dr Freedland also reviews prespecified subgroup analyses and long-term safety